OFIX · Orthofix Medical Inc.
$9.00
-0.20 (-2.17%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$366.59M
Shares
40.73M
Volume · Oct 8
588.1K
Avg daily vol (3M)
368.03K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.00
Open$9.18
Day$8.86–9.30
52W close$8.64–16.23
Avg vol 30d405K
Short int2.5M · 6.2% float · 7.1d
Short vol48%
Last earningsAug 5, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$833.19M
Trailing 12 months
Net income (TTM)
−$61.72M
Trailing 12 months
Revenue growth YoY
+3.8%
Year over year
Operating margin
-4.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.6%
Year over year · more shares
Price change (1Y)
-35.2%
Trailing year
Short interest
6.2%
Latest settlement · 7.1 days to cover
AI Brief
Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26
TL;DR. Orthofix raised full-year 2026 guidance, with net sales now $845M–$855M and adjusted EBITDA $95M–$98M, reflecting the restoration of Medicare reimbursement for bone growth stimulators and an approximate $15M European distributor inventory purchase tied to MDR transition, partially offset by ongoing softness among smaller U.S. spine distributors.
Bullish
- + Raised full-year 2026 net sales guidance to $845M–$855M, an increase of $7M from prior outlook.
- + Raised full-year 2026 adjusted EBITDA guidance to $95M–$98M, returning to the level expected before the Medicare reimbursement reduction.
- + Biologics stabilized at approximately flat year-over-year, the second consecutive quarter of improved performance after double-digit declines in 2025.
Bearish
- − Ongoing softness among smaller U.S. spine distributors expected to continue through the balance of the year.
- − Adjusted gross margin declined to 71.7% from 72.7% in Q2 2025 due to unfavorable geographic mix.
- − European MDR distributor arrangement creates an approximately $22 million net sales headwind in 2027 while MDR requirements are completed.
- − European distributor arrangement creates a temporary free cash flow timing headwind in 2026 as cash receipts are projected in 2027 while inventory cash outflows occur this year.
- − GAAP net loss of $(15.8) million in Q2 2026 with net loss per share of $(0.39).
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
−8%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
5%
near low
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−29%
trailing
YTD return
−41%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
5 of 143 funds reported for Sep 30 · net -1.2K sh shares
Insider flow
Accumulating
Net +$2.3M over 90 days · 67% sells
Short interest
Rising
6.15% of float · ▲ +5.5% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
143 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+3%
Y/Y
Gross margin
69%
expanding
EPS growth
+29%
Y/Y
Free cash flow
$-26.9M
Buyback
$75.0M
authorized
Balance sheet
$75.4M
net debt
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
4.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
full-year 2026
Net sales
Non-GAAP
Initiated
$845M – $855M
Non-GAAP adjusted EBITDA
Non-GAAP
Initiated
$95M – $98M
2026
Adj. EBITDA
Non-GAAP
$95M – $98M
Guided vs delivered
· last 3 settled
Full year net sales
year ended December 31, 2023
guided $739M – $744M
$746.64M
Beat +0.7%
Top line revenue
full year of 2021
guided $460M – $464M
$464.48M
Beat +0.5%
Revenue
first quarter 2021
guided $95M – $96M
$105.59M
Beat +10.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $12 — 200d above 50d
Institutional flow
Distributing
5 of 143 funds reported for Sep 30 · net -1.2K sh shares
Insider flow
Accumulating
Net +$2.3M over 90 days · 67% sells
Short interest
Rising
6.15% of float · ▲ +5.5% MoM · 7.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
143 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $9
Now $9 · 5%
Range high $16
vs 200-day avg -22%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $29.83M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of pro forma net sales non-GAAP | 7.3% | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA as a percentage of reported net sales non-GAAP | 7.3% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margin as a percentage of pro forma net sales non-GAAP | 71.2% | Six Months Ended June 30, 2026 | — |
| Adjusted gross margin as a percentage of reported net sales non-GAAP | 71.2% | Six Months Ended June 30, 2026 | — |
| Adjusted gross profit non-GAAP | $290.11M | Six Months Ended June 30, 2026 | — |
| Adjusted net income (loss) non-GAAP | -$1.69M | Six Months Ended June 30, 2026 | — |
| Free cash flow non-GAAP | -$47.14M | Six Months Ended June 30, 2026 | — |
| Global Limb Reconstruction Segment Adjusted EBITDA non-GAAP | $1.15M | Three Months Ended June 30, 2026 filing | — |
| Global Spine Segment Adjusted EBITDA non-GAAP | $25.59M | Three Months Ended June 30, 2026 filing | — |
| non-GAAP adjusted EBITDA non-GAAP | $20.1M | second quarter 2026 | — |
| Non-GAAP Adjusted Gross Margin non-GAAP | 71.7% | Q2 2026 | — |
| Non-operating expense, as adjusted non-GAAP | $12.89M | Six Months Ended June 30, 2026 | — |
| Pro forma net sales non-GAAP | $210.9M | Q2 FY2026 | — |
| Pro forma net sales growth (constant currency) non-GAAP | 4.7% | Q2 2026 | — |
| Q2 Non-GAAP Adjusted EBITDA non-GAAP | $20.1M | Q2 2026 | — |
| Research and development expense, as adjusted non-GAAP | $30.46M | Six Months Ended June 30, 2026 | — |
| Sales, general, and administrative expense, as adjusted non-GAAP | $262.9M | Six Months Ended June 30, 2026 | — |
| Segment Adjusted EBITDA non-GAAP | $26.74M | Three Months Ended June 30, 2026 filing | — |
| TTM Pro Forma Adj. EBITDA non-GAAP | $84M | TTM as of 6/30/2026 | — |
| TTM Pro Forma Adj. Gross Margin non-GAAP | 71.5% | TTM as of 6/30/2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OFIX
this stock
Orthofix Medical Inc.
|
$366.59M | -40.6% | +2.9% | — | 6.2% |
|
ABT
Abbott Laboratories
|
$171.97B | -21.4% | +5.7% | 27.7 | 1.1% |
|
MDT
Medtronic plc
|
$112.24B | -8.7% | +8.4% | 21.6 | 1.3% |
|
SYK
Stryker Corp
|
$105.64B | -21.2% | +11.2% | 28.5 | 2.0% |
|
BSX
Boston Scientific Corp
|
$60.69B | -55.9% | +12.5% | 17.0 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OFIX | -2.3% | +3.6% | -29.2% | -4.4% | -40.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -3.6% | +1.5% | -38.2% | -5.8% | -54.1% |
Capital returns
Buyback program
· as of Dec 31, 2017
Authorized
$75.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.